October 26

Eli Lilly Prozac UK Fact Sheet: "Not Recommended" for Children – PMDD Withdrawn in UK

Eli Lilly Prozac UK Fact Sheet: “Not Recommended” for Children – PMDD Withdrawn in UK

Fri, 19 Dec 2003

The Alliance for Human Research Protection has obtained copies of two Eli Lilly documents that were sent to all physicians in the UK yesterday.

A letter informs doctors in the UK that Prozac is no longer authorized for use in (so-called) premenstrual dysphoric disorder (PMDD). And Eli Lilly’s new Prozac Fact Sheet sent to UK physicians–but not to US physicians–states that Prozac is NOT RECOMMENDED FOR CHILDREN for any indication.

Reasons given for withdrawal of PMDD indication: “PMDD is not a well-established disease entity across Europe. It is not listed in the International Classification of Diseases.”

This demonstrates the cynicism of drug company giants: Eli Lilly’s marketing invention primarily hurt American women– who were deliberately deluded into believing they suffered from a psychiatric “disease” where none exists.

FDA officials bear a major responsibility for having allowed drug companies to invent diseases–such as PMDD, “social anxiety disorder,” ADHD, “oppositional defiance disorder”–all created in order to expand the market for antidepressant drugs, such as Prozac. American doctors have been participants in this fraudulent marketing scheme.

This calls for women to take action!


Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.


You may also like

September 29, 2022

“Here we will have to really think medical-legal. Why medical-legal? Because [despite] quite a few adverse events

Read More
Israeli Government Officials Concealed Evidence Documenting Irreparable Harm Following Covid-19 Jabs

September 20, 2022

Stop the World Health Organization Treaty that would dictate global public health policy — in other words,

Read More
Vera Sharav Statement Against Efforts by the World Health Organization to Dictate Global Health Policy